Department of Clinical Pharmacology, School of Health Sciences, Aristotle University of Thessaloniki, University Campus, Thessaloniki, Greece.
Expert Rev Respir Med. 2021 Aug;15(8):979-983. doi: 10.1080/17476348.2021.1951239. Epub 2021 Jul 8.
: The Coronavirus disease 2019 (COVID-19) poses novel challenges in the healthcare systems around the world. Concern about the role of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and, in particular, ibuprofen has led to significant speculation.: A literature search was conducted to evaluate ibuprofen's potential benefits and harms in the COVID-19 disease. Angiotensin-Converting Enzyme 2 (ACE-2) is crucial entry receptor for Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) in host cells. We found no scientific evidence linking ibuprofen use and an ACE-2 overexpression. Ibuprofen suppresses the production of various pro-inflammatory cytokines that are implicated in the 'cytokine storm' and subsequent ARDS in COVID-19 disease. Nevertheless, the exact role of ibuprofen in the immune response in COVID-19 disease is still unknown. There are no double-blind, placebo-controlled studies assessing the effect of ibuprofen on COVID-19 disease progression.: The studies that have been performed so far demonstrate no association between ibuprofen use and increased mortality rates or an increased risk for respiratory support. Accordingly, we recommend ibuprofen to be used for managing COVID-19 symptoms.
: 2019 年冠状病毒病（COVID-19）给全球医疗体系带来了新的挑战。人们对非甾体抗炎药（NSAIDs）的作用，特别是布洛芬的作用产生了极大的关注，这导致了大量的猜测。: 我们进行了文献检索，以评估布洛芬在 COVID-19 疾病中的潜在益处和危害。血管紧张素转换酶 2（ACE-2）是宿主细胞中严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）的关键进入受体。我们没有发现将布洛芬使用与 ACE-2 过表达联系起来的科学证据。布洛芬抑制各种促炎细胞因子的产生，这些细胞因子与 COVID-19 疾病中的“细胞因子风暴”和随后的急性呼吸窘迫综合征（ARDS）有关。然而，布洛芬在 COVID-19 疾病中的免疫反应中的确切作用仍不清楚。目前还没有双盲、安慰剂对照研究评估布洛芬对 COVID-19 疾病进展的影响。: 迄今为止进行的研究表明，布洛芬的使用与死亡率增加或呼吸支持风险增加之间没有关联。因此，我们建议使用布洛芬来治疗 COVID-19 症状。
